Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 6, 2016, Pages 1332-1342

  Luckett, Rebecca ^a   Feldman, Sarah ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cervical cancer; HPV vaccines; morbidity; mortality

Indexed keywords

BIVALENT WART VIRUS VACCINE; QUADRIVALENT WART VIRUS VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); CROSS PROTECTION; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; META ANALYSIS (TOPIC); MORBIDITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VACCINATION; COMPLICATION; FEMALE; INCIDENCE; MORTALITY; PAPILLOMAVIRUS INFECTION; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 84961392683     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1108500     Document Type: Review

References (105)

1. L.Torre, F.Bray, R.Siegel, J.Ferlay, J.Lortet-Tieulent, J.Ahmedin. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65:87-108; http://dx.doi.org/10.3322/caac.21262
2. J.Ferlay, I.Soerjomataram, M.Ervik, R.Dikshit, S.Eser, C.Mathers, M.Rebelo, D.M.Parkin, D.Forman, F.Bray,. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. Eleven [Internet]. Lyon, France: International Agency for Research on Cancer 2013 Available from http://globocan.iarc.fr
3. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Cancer Statistics Review (1973–2012), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015. Accessed 6/25/2015
4. A.Olusola, S.Kulasignam, B.Virnig. Cervical cancer trends in the United States: A 35-year population-based analysis. J Womens Health 2012; 21(10):1031-7; http://dx.doi.org/10.1089/jwh.2011.3385
5. R.Reid, C.R.Stanhope, B.R.Herschman, E.Booth, G.D.Phibbs, J.P.Smith. Genital warts and cervical cancer. I Evidence of an association between subclinical papillomavirus infection and cervical malignancy. Cancer 1982; 50(2):377-87; PMID:6282442; http://dx.doi.org/10.1002/1097-0142(19820715)50:2<377::AID-CNCR2820500236>3.0.CO;2-A
6. A.Asiaf, S.Ahmad, S.Mohammad, M.Zargar. Review of the current knowledge on the epidemiology, pathogenesis, and prevention of huma papillomavirus infection. Eur J Can Prev 2014; 23:206-24; http://dx.doi.org/10.1097/CEJ.0b013e328364f273
7. M.Nobbenhuis, J.Walboomers, T.Helmerhorst, L.Rozendaal, A.Remmink, E.K.Risse, H.C.van der Linden, F.J.Voorhorst, P.Kenemans, C.J.Meijer, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354:20-5; PMID:10406360; http://dx.doi.org/10.1016/S0140-6736(98)12490-X
8. A.Rositch, A.Burke, R.Viscidi, M.Silver, K.Chang, P.Gravitt. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: Acquisition and reactivation in older women. Cancer Res 2012; 72(23):6183-90; PMID:23019223; http://dx.doi.org/10.1158/0008-5472.CAN-12-2635
9. P.Gravitt, A.Rositch, M.Silver, M.Marks, K.Change, A.Burke, R.P.Viscidi. A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis 2013; 207:272-80; PMID:23242540; http://dx.doi.org/10.1093/infdis/jis660
10. C.de Martel, J.Ferlay, S.Franceschi, J.Vignat, F.Bray, D.Forman, M.Plummer. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13:607-15; PMID:22575588; http://dx.doi.org/10.1016/S1470-2045(12)70137-7
11. L.Peirson, D.Fitzpatrick-Lewis, D.Ciliska, R.Warren. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev 2013; 2:35; PMID:23706117; http://dx.doi.org/10.1186/2046-4053-2-35
12. European Centre for Disease Prevention and Control. Guidance for the introduction of HPV vaccines in EU countries. 2008 Accessed 20July2015: http://ecdc.europa.eu/en/Documents/4940_0801_HPV_guidance.pdf
13. G.Engholm, J.Ferlay, N.Christensen, et al; Association of the Nordic Cancer Registries; Danish Cancer Society. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries. Version 6.1 (25.04.2014). ancr.nu. Accessed June25, 2015
14. Cancer in Norway 2009. Special issue: Cancer screening in Norway (T.Haldorsen, ed) Cancer Registry of Norway, Oslo, 2011
15. R.Gibb, M.G.Martens. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol 2011; 4(Suppl 1):S2-S11; PMID:21617785
16. World Health Organization. WHO guidance note: comprehensive cervical cancer prevention and control: a healthier future for girls and women. Geneva 2013
17. D.V.Coleman, J.J.Poznansky. Review of cervical smears from 76 women with invasive cervical cancer: cytological findings and medicolegal implications. Cytopath 2006; 17:127-36; http://dx.doi.org/10.1111/j.1365-2303.2006.00310.x
18. S.Glick, A.Clarke, A.Blanchard, A.K.Whitaker. Cervical cancer screening, diagnosis and treatment interventions for racial and ethnic minorities: A Systematic Review. J Gen Intern Med 2012; 27(8):1016-32; PMID:22798213; http://dx.doi.org/10.1007/s11606-012-2052-2
19. D.M.Chase, K.Osann, N.Sepina, L.Wenzel, K.S.Tewari. The challenge of follow-up in a low-income colposcopy clinic: characteristics associated with noncompliance in high-risk populations. J Low Genit Tract Dis 2012; 16(4):345-51; PMID:22622340; http://dx.doi.org/10.1097/LGT.0b013e318249640f
20. R.Sankaranarayanan, R.Anorlu, G.Sangwa-Lugoma, L.Denny. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in Sub-Saharan Africa. Vaccine 2013; 31S:F47-52; http://dx.doi.org/10.1016/j.vaccine.2012.06.066
21. S.A.Sabatino, M.C.White, T.D.Thompson, C.N.Klabunde. Cancer screening test use – United States, 2013. MMWR Morb Mortal Wkly Repo 2015; 64(17):464-8
22. N.Munoz, F.Bosch, S.De Sanjose, R.Herrero, X.Castellsague, K.V.Shah, P.J.Snijders, C.J.Meijer. Epidemiologic classification of human papillomavirus types associated with cervical cancer. NEJM 2003; 348(6):518-27; PMID:12571259; http://dx.doi.org/10.1056/NEJMoa021641
23. A.B.Moscicki, Y.Ma, C.Wibbelsman, T.M.Darragh, A.Powers, S.Farhat, S.Shiboski. Rate of and risks for regression of CIN-2 in adolescents and young women. Obstet Gynecol 2010; 116:1373-80; PMID:21099605; http://dx.doi.org/10.1097/AOG.0b013e3181fe777f
24. P.E.Castle, M.Schiffman, C.M.Wheeler, D.Solomon. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009; 113:18; PMID:19104355; http://dx.doi.org/10.1097/AOG.0b013e31818f5008
25. M.R.McCredie, K.J.Sharples, C.Paul, J.Baranyai, G.Medley, R.W.Jones, D.C.Skegg. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9:425-34; PMID:18407790; http://dx.doi.org/10.1016/S1470-2045(08)70103-7
26. C.Wheeler. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin N Am 2008; 35:519-36; http://dx.doi.org/10.1016/j.ogc.2008.09.006
27. G.M.Clifford, S.Gallus, R.Herrero, N.Munoz, J.F.Snijders, S.Vaccarella, P.T.Anh, C.Ferreccio, N.T.Hieu, E.Matos, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366:991-8; PMID:16168781; http://dx.doi.org/10.1016/S0140-6736(05)67069-9
28. S.de Sanjose, M.Diaz, X.Castellsague, G.Clifford, L.Bruni, N.Munoz, F.X.Bosch. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7:453-9; PMID:17597569; http://dx.doi.org/10.1016/S1473-3099(07)70158-5
29. E.F.Dunne, E.R.Unger, M.Sternberg, G.McQuilan, D.C.Swan, S.S.Patel, L.E.Markowitz. Prevalence of HPV infection among females in the United States. JAMA 2007; 297(8):813-9; PMID:17327523; http://dx.doi.org/10.1001/jama.297.8.813
30. C.Banura, S.Franceschi, L.van Doorn, A.Arslan, F.Wabwire-Mangen, E.K.Mbidde, W.Quint, E.Weiderpass. Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis 2008; 197:555-62; http://dx.doi.org/10.1086/526792
31. P.Oakeshott, A.Aghaizu, F.Reid, R.Howell-Jones, P.E.Hay, S.T.Sadiq, C.J.Lacey, S.Beddows, K.Soldan. Frequency and risk factors for prevalent, incident and persistent genital carcinomgenic human papillomavirus infection in sexually active women: community based cohort study. BMJ 2012; 344:e4168; PMID:22730542; http://dx.doi.org/10.1136/bmj.e4168
32. G.Ho, R.Bierman, L.Beardsley, C.Chang, R.Burk. Natural history of cervicovaginal papillomavirus infection in young women. NEJM 1998; 338(7):423-8; PMID:9459645; http://dx.doi.org/10.1056/NEJM199802123380703
33. J.M.Walboomers, M.V.Jacobs, M.M.Manos, F.X.Bosch, J.A.Kummer, K.V.Shah, P.J.Snijders, J.Peto, C.J.Meijer, N.Muñoz. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19; PMID:10451482; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
34. K.Wallin, F.Wiklund, T.Angstrom, F.Bergman, U.Stendahl, G.Wadell, G.Hallmans, J.Dillner. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. NEJM 1999; 341(22):1633-8; PMID:10572150; http://dx.doi.org/10.1056/NEJM199911253412201
35. G.M.Clifford, J.S.Smith, M.Plummer, N.Munoz, S.Franceschi. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Brit J Cancer 2003; 88:63-73; PMID:12556961; http://dx.doi.org/10.1038/sj.bjc.6600688
36. J.Smith, L.Lindsay, B.Hoots, J.Keys, S.Franceschi, R.Winer, G.M.Clifford. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007; 121:621-32; PMID:17405118; http://dx.doi.org/10.1002/ijc.22527
37. S.de Sanjose, W.G.Quint, L.Alemany, D.T.Geraets, J.E.Klaustermeier, B.Lloveras, S.Tous, A.Felix, L.E.Bravo, H.R.Shin, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8
38. C.D.Harro, Y.Y.Pang, R.B.Roden, A.Hildesheim, Z.Wang, M.J.Reynolds, T.C.Mast, R.Robinson, B.R.Murphy, R.A.Karron, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93(4):284; PMID:11181775; http://dx.doi.org/10.1093/jnci/93.4.284
39. US. Food and Drug Administration. Approval letter – human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant. Eight June 2006. Accessed on 20July2015 at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm111283.htm
40. US. Food and Drug Administration News Release. FDA approves new vaccine for prevention of cervical cancer. Sixteen October 2009. Accessed on 20July2015 at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187048.htm
41. European Centre for Disease Prevention and Control. HPV vaccination in EU countries: review of new evidence. Twenty-three Apr 2014. Accessed 14August2015 at: http://ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=758
42. R.Herrero, P.Gonzalez, L.E.T.Markowitz. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol 2015; 16(5):e206-16; PMID:25943065; http://dx.doi.org/10.1016/S1470-2045(14)70481-4
43. L.Markowitz, V.Tsu, S.Deeks, H.Cubie, S.Wang, A.Vicari, J.M.Brotherton. Human papillomavirus vaccine introduction – the first five years. Vaccine 2012; 30S:F139-148; http://dx.doi.org/10.1016/j.vaccine.2012.05.039
44. D.S.LaMontagne, S.Barge, N.T.Le, E.Mugisha, M.E.Penny, S.Gandhi, A.Janmohamed, E.Kumakech, N.R.Mosqueira, N.Q.Nguyen, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011; 89:821B-30B; http://dx.doi.org/10.2471/BLT.11.089862
45. A.Binagwaho, C.M.Wagner, M.Gatera, C.Karema, C.T.Nutt, F.Ngabo. Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme. Bull World Health Organ 2012; 90(8):623-8; PMID:22893746; http://dx.doi.org/10.2471/BLT.11.097253
46. J.Paavonen, P.Naud, J.Salmeron, C.M.Wheeler, S.N.Chow, D.Apter, H.Kitchener, X.Castellsague, J.C.Teixeira, S.R.Skinner, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
47. A.Kreimer, P.Gonzalez, H.Katki, C.Porras, M.Schiffman, A.Rodriguez, D.Solomon, S.Jiménez, J.T.Schiller, D.R.Lowy, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011; 12:862-70; http://dx.doi.org/10.1016/S1470-2045(11)70213-3
48. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomized placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-85; PMID:19962185; http://dx.doi.org/10.1016/S0140-6736(09)61567-1
49. P.Naud, C.M.Roteli-Martins, N.S.DeCarvalho, J.C.Teixeira, P.C.de Borba, N.Sanchez, T.Zahaf, G.Catteau, B.Geeraerts, D.Descamps. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine. Hum Vac Immunother 2014; 10:2147-62; http://dx.doi.org/10.4161/hv.29532
50. D.M.Harper, E.L.Franco, C.M.Wheeler, A.B.Moscicki, B.Romanowski, C.M.Roteli-Martins, D.Jenkins, A.Schuind, S.A.Costa Clemens, G.Dubin. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006; 367:1247-55; PMID:16631880; http://dx.doi.org/10.1016/S0140-6736(06)68439-0
51. L.Villa, G.Perez, S.Kjaer, J.Paavonen, M.Lehtinen, N.Munoz, et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. NEJM 2007; 356(19):1915-27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741
52. S.Garland, M.Hernandez-Avila, C.Wheeler, G.Perez, D.Harper, S.Leodolter, G.W.Tang, D.G.Ferris, M.Steben, J.Bryan, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. NEJM 2007; 356(19):1928-43; PMID:17494926; http://dx.doi.org/10.1056/NEJMoa061760
53. S.Block, T.Nolan, C.Sattler, E.Barr, K.E.Giacoletti, C.D.Marchant. Comparison of the immunogenicity and reactogeniity of a prophylactic quadrivalent human papillomavirus (types 6,11,16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-45; PMID:17079588; http://dx.doi.org/10.1542/peds.2006-0461
54. L.Villa, K.Ault, A.Giuliano, R.Cost, C.Petta, R.Andrade, D.R.Brown, A.Ferenczy, D.M.Harper, L.A.Koutsky, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, 18. Vaccine 2006; 24:5571-83; PMID:16753240; http://dx.doi.org/10.1016/j.vaccine.2006.04.068
55. D.Brown, S.K.KjaerK.Sigurdsson, O.E.Iversen, M.Hernandez-Avila, C.M.Wheeler, G.Perez, L.A.Koutsky, E.H.Tay, P.Garcia, et al. The impact of quadrivalent human papillomavirus (HPV; Types 6,11,16, and 18):L1 virus-like particle vaccine on infection and disease due to oncogenc nonvaccine HPV types in generally HPV-naïve women aged 16-26 years. J Infect Dis 2009; 199:926-35; PMID:19236279; http://dx.doi.org/10.1086/597307
56. C.M.Wheeler, S.K.Kjaer, K.Sigurdsson, O.E.Iversen, M.Hernandez-Avila, G.Perez, D.R.Brown, L.A.Koutsky, E.H.Tay, P.García, et al. The impact of quadrivalent human papillomavirus (HPV; Types 6,11,16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199:936-44; PMID:19236277; http://dx.doi.org/10.1086/597309
57. T.Malagon, M.Drolet, M.C.Boily, E.L.Franco, M.Jit, J.Brisson, M.Brisson. Cross-protective efficacy of two human papillomavirus vaccines: as systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781-9; PMID:22920953; http://dx.doi.org/10.1016/S1473-3099(12)70187-1
58. D.Lowry, R.Herrero, A.Hildesheim. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol 2015; 16:e226-33; PMID:25943067; http://dx.doi.org/10.1016/S1470-2045(15)70075-6
59. A.C.Rodríguez, D.Solomon, R.Herrero, A.Hildesheim, P.González, S.Wacholder, C.Porras, S.Jiménez, M.Schiffman; CVT Group. Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am J Epidemiol 2013; 178(5):752-60; http://dx.doi.org/10.1093/aje/kwt047
60. N.Munoz, S.K.Kjaer, K.Sigurdsson, O.E.Iversen, M.Hernandez-Avila, C.M.Wheeler, G.Perez, D.R.Brown, L.A.Koutsky, E.H.Tay, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102(5):325-39; PMID:20139221; http://dx.doi.org/10.1093/jnci/djp534
61. L.E.Markowitz, E.Dunne, M.Saraiya, H.W.Chesson, C.R.Curtis, J.Gee, J.A.BocchiniJr, E.R.Unger. Human papillomavirus vaccination: Recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Repo 2014; 63(RR05):1-30
62. M.Einstein, M.Baron, M.J.Levin, A.Chatterjee, R.P.Edwards, F.Zepp, I.Carletti, F.J.Dessy, A.F.Trofa, A.Schuind, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Human Vaccines 2009; 5(10):705-19; PMID:19684472; http://dx.doi.org/10.4161/hv.5.10.9518
63. J.Brotherton, M.Fridman, C.May, G.Chappell, A.M.Saville, D.Gertig. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377:2085-92; PMID:21684381; http://dx.doi.org/10.1016/S0140-6736(11)60551-5
64. S.N.Tabrizi, J.M.Brotherton, J.M.Kaldor, S.R.Skinner, E.Cummins, B.Liu, D.Bateson, K.McNamee, M.Garefalakis, S.M.Garland. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206:1645-51; PMID:23087430; http://dx.doi.org/10.1093/infdis/jis590
65. S.Tabrizi, J.Brotherton, J.Kaldor, S.R.Skinner, B.Liu, D.Bateson, K.McNamee, M.Garefalakis, S.Phillips, E.Cummins, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014; 14(10):958-66; PMID:25107680; http://dx.doi.org/10.1016/S1473-3099(14)70841-2
66. L.E.Markowitz, S.Hariri, C.Lin, E.F.Dunne, M.Steinau, G.McQuillan, E.R.Unger. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385-93; PMID:23785124; http://dx.doi.org/10.1093/infdis/jit192
67. S.Stokley, J.Jeyarajah, D.Yankey, M.Cano, J.Gee, J.Roark, R.C.Curtis, L.Markowitz. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014 – United States. MMWR Morb Mortal Wkly Repo 2014; 63(29):620-4
68. S.Reagan-Steiner, D.Yankey, J.Jeyarajah, L.Elam-Evans, J.Singleton, C.R.Curtis, J.MacNeil, L.E.Markowitz, S.Stokley. National, regional, state and selected local area vaccination coverage among adolescents aged 13-17 years – United States 2014. MMWR Morb Mortal Wkly Repo 2015; 64(29):784-92; http://dx.doi.org/10.15585/mmwr.mm6429a3
69. B.Baldur-Felskov, C.Dehlendorff, C.Munk, S.Kjaer. Early impact of human papillomavirus vaccination on cervical neoplasia – nationwide follow-up of young Danish women. J Natl Cancer Inst 2014; 106(3):djt460; PMID:24552678; http://dx.doi.org/10.1093/jnci/djt460
70. M.Drolet, E.Benard, M.C.Boily, H.Ali, L.Baandrup, H.Bauer, S.Beddows, J.Brisson, J.M.Brotherton, T.Cummings, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15:565-80; PMID:25744474; http://dx.doi.org/10.1016/S1473-3099(14)71073-4
71. L.M.Niccolai, P.J.Julian, J.I.Meek, V.McBride, J.L.Hadler, L.E.Sosa. Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. Cancer Epidemiol Biomarkers Prev 2013; 22:1446-50; PMID:23704476; http://dx.doi.org/10.1158/1055-9965.EPI-13-0272
72. D.Mesher, K.Soldan, R.Howell-Jones, K.Panwar, P.Manyenga, M.Jit, S.Beddows, O.N.Gill. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunization in England. Vaccine 2014; 32:26-32; http://dx.doi.org/10.1016/j.vaccine.2013.10.085
73. US. Food and Drug Administration News Release. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. Ten December 2014. Accessed on 1July2015 at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm
74. E.A.Joura, A.R.Giuliano, O.E.Iversen, C.Bouchard, C.Mao, J.Mehlsen, E.D.MoreiraJr, Y.Ngan, L.K.Petersen, E.Lazcano-Ponce, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372(8):711-23; PMID:25693011; http://dx.doi.org/10.1056/NEJMoa1405044
75. D.Riethmuller, A.C.Jacquard, J.St Guily, F.Aubin, X.Carcopino, P.Pradat, A.Dahlab, J.L.Prétet. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health 2015; 15:453-59; PMID:25934423; http://dx.doi.org/10.1186/s12889-015-1779-1
76. S.Hariri, E.R.Unger, S.Schafer, L.M.Niccolai, I.U.Park, K.C.Block, N.M.Bennett, M.Steinau, M.L.Johnson, L.E.Markowitz. HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States. Cancer Epidemiol Biomarkers Prev 2015; 24(2):393-9; PMID:25416715; http://dx.doi.org/10.1158/1055-9965.EPI-14-0649
77. N.Van de Velde, M.C.Coily, M.Drolet, E.Franco, M.H.Mayrand, E.V.Kliewer, F.Coutlée, J.F.Laprise, T.Malagón, M.Brisson. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012; 104(22):1712-23; PMID:23104323; http://dx.doi.org/10.1093/jnci/djs395
78. Food and Drug Administration. Product approval-prescribing information [Package insert]. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant], Merck & Co, Inc. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf
79. Food and Drug Administration. Product approval-prescribing information [Package insert]. Cervarix [human papillomavirus bivalent (types 16, 18) vaccine, recombinant], Glaxo Smith Kline. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf
80. Food and Drug Administration. Product approval-prescribing information [Package insert]. Gardasil9 [human papillomavirus 9-valent vaccine, recombinant], Merck & Co, Inc. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf
81. D.Descamps, K.Hardt, B.Spiessens, P.Izurieta, T.Verstraeten, T.Breuer, G.Dubin. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009; 5:332-40; PMID:19221517; http://dx.doi.org/10.4161/hv.5.5.7211
82. T.Verstraeten, D.Descamps, M.P.David, T.Zahaf, K.Hardt, P.Izurieta, G.Dubin, T.Breuer. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26:6630-8; PMID:18845199; http://dx.doi.org/10.1016/j.vaccine.2008.09.049
83. B.Slade, L.Leidel, C.Vellozzi, E.J.Woo, W.Hua, A.Sutherland, H.S.Izurieta, R.Ball, N.Miller, M.M.Braun, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302(7):750-57; PMID:19690307; http://dx.doi.org/10.1001/jama.2009.1201
84. J.Gee, A.Naleway, I.Shui, J.Baggs, R.Yin, R.Li, M.Kulldorff, E.Lewis, B.Fireman, M.F.Daley, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011; 29:8279-84; PMID:21907257; http://dx.doi.org/10.1016/j.vaccine.2011.08.106
85. C.Chao, N.P.Klein, C.M.Velicer, L.S.Sy, J.M.Slezak, H.Takhar, B.Ackerson, T.C.Cheetham, J.Hansen, K.Deosaransingh, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012; 271:193-203; PMID:21973261; http://dx.doi.org/10.1111/j.1365-2796.2011.02467.x
86. L.Arnheim-Dahlstrom, B.Pasternak, H.Svanstrom, P.Sparen, A.Hviid. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347:f5906; PMID:24108159; http://dx.doi.org/10.1136/bmj.f5906
87. L.Grimaldi-Bensouda, D.Guillemot, B.Godeau, J.Bénichou, C.Lebrun-Frenay, C.Papeix, P.Labauge, P.Berquin, A.Penfornis, P.Y.Benhamou, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014; 275:398-408; PMID:24206418; http://dx.doi.org/10.1111/joim.12155
88. K.K.Macartney, C.Chiu, M.Georgousakis, J.M.Brotherton. Safety of human papillomavirus vaccines: a review. Drug Saf 2013; 36:393-412; PMID:23637071; http://dx.doi.org/10.1007/s40264-013-0039-5
89. M.A.Goss, F.Lievano, M.M.Seminack, A.Dana. No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy: 6-year pregnancy registry data. Obstet Gynecol 2014; 123(Suppl 1):93S; http://dx.doi.org/10.1097/01.AOG.0000447430.00051.ba
90. J.P.Buttery, S.Madin, N.W.Crawford, S.Elia, S.La Vincente, S.Hanieh, L.Smith, B.Bolam. Mass psychogenic response to human 23 papillomavirus vaccination. Med J Aust 2008; 189:261-2; PMID:18759721
91. M.Martinez-Lavin. Hypothesis: Human papillomavirus vaccination syndrome – small fiber neuropathy and dysautonomia could be its underlying pathogenesis. Clin Rheumatol 2015; 34:1165-9; PMID:25990003; http://dx.doi.org/10.1007/s10067-015-2969-z
92. S.Blitshteyn. Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol 2014; 21:135-9; PMID:24102827; http://dx.doi.org/10.1111/ene.12272
93. T.Kinoshita, R.T.Abe, A.Hineno, K.Tsunekawa, S.Nakane, S.Ikeda. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papilloma- virus vaccine. Intern Med 2014; 53:2185-200; PMID:25274229; http://dx.doi.org/10.2169/internalmedicine.53.3133
94. L.Brinth, A.C.Theibel, K.Pors, J.Mehlsen. Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J, 2015; 62:A5064
95. World Health Organization. Weekly Epidemiological Record. 2013; 88:301-12. Available at http://www.who.int/wer/2013/wer8829.pdf?ua=1; PMID:23909011
96. D.Apter, C.Wheeler, J.Paavonen, X.Castellsague, S.Garland, R.Skinner, P.Naud, J.Salmerón, S.N.Chow, H.C.Kitchener, et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: Final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine IMmunol 2015; 22(4):361-73; PMID:25651922; http://dx.doi.org/10.1128/CVI.00591-14
97. M.Jit, M.Brisson, A.Portnoy, R.Hutubessy. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health 2014; 2:e406-14; PMID:25103394; http://dx.doi.org/10.1016/S2214-109X(14)70237-2
98. M.Nakalembe, F.Mirembe, C.Banura. Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy. Infect Agents Can 2015; 10:17; http://dx.doi.org/10.1186/s13027-015-0012-2
99. Gavi The Vaccine Alliance. Factsheet on human papillomavirus. February 2014. Accessed on 21July2015 at: http://www.gavi.org/support/nvs/human-papillomavirus-vaccine-support/
100. US. Food and Drug Administration. Approval letter – Gardasil. Sixteen October 2009. Accessed on 20July2015 at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186991.htm
101. M.Lehtinen, J.Dillner. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013; 10:400-10; PMID:23736648; http://dx.doi.org/10.1038/nrclinonc.2013.84
102. P.Crosignani, A.De Stefani, G.Fara, A.Isidori, A.Lenzi, C.A.Liverani, A.Lombardi, F.S.Mennini, G.Palu', S.Pecorelli, et al. Towards the eradication of HPV infection through universal specific vaccination. BMC Public Health 2013; 13:642-52; PMID:23845195; http://dx.doi.org/10.1186/1471-2458-13-642
103. K.Sinka, K.Kavanagh, R.Gordon, J.Love, A.Potts, M.Donaghy, C.Robertson. Achieving high and equitable coverage of adolescent HPV vaccine in Scotland. J Epidemiol Community Health 2014; 68(1):57-63; PMID:23986492; http://dx.doi.org/10.1136/jech-2013-202620
104. B.Erickson, E.Landers, W.Huh. Update on vaccination clinical trials for HPV-related disease. Clin Therap 2014; 36(1):8-16; http://dx.doi.org/10.1016/j.clinthera.2013.11.003
105. A.Jemal, E.P.Simard, C.Dorell, A.M.Noone, L.E.Markowitz, B.Kohler, C.Eheman, M.Saraiya, P.Bandi, D.Saslow, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105(3):175; PMID:23297039; http://dx.doi.org/10.1093/jnci/djs491